Fig. 5B shows that tumors of mice treated with cisplatin, CpG and PADRE had a significantly lower percentage of CD11b+ Ly6GHi MDSCs in the tumor loci compared to all other treatment groups. This evidence concerns the gene ITGAM and neoplasm.